These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9925184)

  • 1. An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol.
    Zhang-Wong J; Beiser M; Zipursky RB; Bean G
    Psychiatry Res; 1998 Dec; 81(3):333-9. PubMed ID: 9925184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
    Lane HY; Chang WH; Chang YC; Hu OY; Lin HN; Jann MW; Hu WH
    Psychiatry Res; 1997 Sep; 72(2):127-32. PubMed ID: 9335203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal haloperidol dosage in first-episode psychosis.
    Zhang-Wong J; Zipursky RB; Beiser M; Bean G
    Can J Psychiatry; 1999 Mar; 44(2):164-7. PubMed ID: 10097837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis.
    Oosthuizen P; Emsley R; Jadri Turner H; Keyter N
    Int J Neuropsychopharmacol; 2004 Jun; 7(2):125-31. PubMed ID: 15003147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol.
    Oosthuizen PP; Emsley RA; Maritz JS; Turner JA; Keyter N
    J Clin Psychiatry; 2003 Sep; 64(9):1075-80. PubMed ID: 14628983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
    Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
    Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting.
    Darby JK; Pasta DJ; Dabiri L; Clark L; Mosbacher D
    J Clin Psychopharmacol; 1995 Oct; 15(5):334-40. PubMed ID: 8830064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haloperidol and prolactin concentrations in Asians and Caucasians.
    Lin KM; Poland RE; Lau JK; Rubin RT
    J Clin Psychopharmacol; 1988 Jun; 8(3):195-201. PubMed ID: 3379143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.
    Jann MW; Fidone GS; Hernandez JM; Amrung S; Davis CM
    Psychiatry Res; 1989 May; 28(2):153-9. PubMed ID: 2568651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients.
    Esel E; Basturk M; Saffet Gonul A; Kula M; Tayfun Turan M; Yabanoglu I; Sofuoglu S
    Psychoneuroendocrinology; 2001 Aug; 26(6):641-7. PubMed ID: 11403983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients.
    Lin KM; Poland RE; Nuccio I; Matsuda K; Hathuc N; Su TP; Fu P
    Am J Psychiatry; 1989 Oct; 146(10):1307-11. PubMed ID: 2782476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients.
    Hesslinger B; Normann C; Langosch JM; Klose P; Berger M; Walden J
    J Clin Psychopharmacol; 1999 Aug; 19(4):310-5. PubMed ID: 10440457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.
    Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R
    Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
    J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactin levels and effects of neuroleptics.
    Brown WA
    Psychosomatics; 1983 Jun; 24(6):569-74, 577-81. PubMed ID: 6136065
    [No Abstract]   [Full Text] [Related]  

  • 16. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
    Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
    Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profile of risperidone.
    Ereshefsky L; Lacombe S
    Can J Psychiatry; 1993 Sep; 38 Suppl 3():S80-8. PubMed ID: 7504573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia.
    Bisol LW; Brunstein MG; Ottoni GL; Ramos FL; Borba DL; Daltio CS; de Oliveira RV; Paz GE; de Souza SE; Bressan RA; Lara DR
    J Clin Psychiatry; 2008 Oct; 69(10):1572-9. PubMed ID: 19192440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
    Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
    Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.